Trial intelligence / Profile preview

Cobicistat vs Ritonavir for Darunavir Brain Permeation in HIV

NCT02503462Phase 4Terminated

Sponsor
University Hospital Basel
Start
Jul 2015
Primary completion
Jan 2017
Modality
Small Molecules
Countries
1
01

Overview

Phase 4, open-label trial of cobicistat in human immunodeficiency virus infection (HIV), sponsored by University Hospital Basel. Primary endpoint: Cerebrospinal fluid/plasma concentrations of darunavir at 1 month. Started Jul 2015; status: terminated.

02

Drugs

cobicistat
03

Conditions

human immunodeficiency virus infection (HIV)

Beyond the preview

Go deeper on NCT02503462.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02503462.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call